American Trust’s Cardlytics CDLX Stock Holding History

American Trust’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-702	Closed	-$386K	–	454
2022 Q1	$386K	Buy	702 +257	+58%	+$155K	0.03%	293
2021 Q4	$294K	Buy	+445	New	+$340K	0.02%	243

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

ACM

Alua Capital Management New York $1.13B AUM 8.41% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

JCM

JS Capital Management New York $109M AUM 34.13% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

American Trust's CDLX Position: Q2 2022 in Review

American Trust sold out of Cardlytics (CDLX) in Q2 2022, closing a stake of 702 shares — an estimated $386K sold.

American Trust first reported a position in CDLX in Q4 2021 and held it in 2 quarters. The position peaked at $386K in Q1 2022. 138 funds tracked by Wall St. Rank hold CDLX as of Q2 2022.

American Trust reported no remaining Cardlytics position as of Q2 2022 after selling out during the quarter.
American Trust sold 702 Cardlytics shares in Q2 2022, an estimated $386K.
American Trust first reported a position in Cardlytics in Q4 2021 and held it in 2 quarters.
American Trust's Cardlytics position peaked at $386K in Q1 2022.
138 funds tracked by Wall St. Rank held Cardlytics as of Q2 2022.

Based on American Trust's 13F filing for Q2 2022, filed 3 Oct 2022.